Entendiendo las terapias actuales en melanoma metastásico

Cutaneous melanoma is a highly aggressive tumor developing from melanocytes, its incidence is increasing, and prognosis in advanced stages is daunting. New therapies have been approved during the recent years with unprecedented results, including inhibitors of MAPK/ERK pathway and immune checkpoint...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rodríguez,Rocío, Parra,Angela, González,Sergio, Molgó,Montserrat, Droppelmann,Nicolás, Acevedo,Francisco, Peña,José, Uribe,Pablo
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2016
Materias:	CTLA-4 Antigen Melanoma Molecular Targeted Therapy Pembrolizumab Programmed Cell Death 1 Receptor
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872016001100011
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872016001100011
record_format	dspace
spelling	oai:scielo:S0034-988720160011000112017-01-25Entendiendo las terapias actuales en melanoma metastásicoRodríguez,RocíoParra,AngelaGonzález,SergioMolgó,MontserratDroppelmann,NicolásAcevedo,FranciscoPeña,JoséUribe,Pablo CTLA-4 Antigen Melanoma Molecular Targeted Therapy Pembrolizumab Programmed Cell Death 1 Receptor Cutaneous melanoma is a highly aggressive tumor developing from melanocytes, its incidence is increasing, and prognosis in advanced stages is daunting. New therapies have been approved during the recent years with unprecedented results, including inhibitors of MAPK/ERK pathway and immune checkpoint blockade (anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) as ipilimumab, anti-programmed cell death protein 1 (PD-L1) as pembrolizumab and anti-programmed cell death protein 1 ligand (PD-L1), among many others). The aim of this paper is to review currently available metastatic melanoma therapies focusing mainly on new therapies that have demonstrated effectiveness, after several decades of little progress in the treatment of this disease.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.144 n.11 20162016-11-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872016001100011es10.4067/S0034-98872016001100011
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	CTLA-4 Antigen Melanoma Molecular Targeted Therapy Pembrolizumab Programmed Cell Death 1 Receptor
spellingShingle	CTLA-4 Antigen Melanoma Molecular Targeted Therapy Pembrolizumab Programmed Cell Death 1 Receptor Rodríguez,Rocío Parra,Angela González,Sergio Molgó,Montserrat Droppelmann,Nicolás Acevedo,Francisco Peña,José Uribe,Pablo Entendiendo las terapias actuales en melanoma metastásico
description	Cutaneous melanoma is a highly aggressive tumor developing from melanocytes, its incidence is increasing, and prognosis in advanced stages is daunting. New therapies have been approved during the recent years with unprecedented results, including inhibitors of MAPK/ERK pathway and immune checkpoint blockade (anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) as ipilimumab, anti-programmed cell death protein 1 (PD-L1) as pembrolizumab and anti-programmed cell death protein 1 ligand (PD-L1), among many others). The aim of this paper is to review currently available metastatic melanoma therapies focusing mainly on new therapies that have demonstrated effectiveness, after several decades of little progress in the treatment of this disease.
author	Rodríguez,Rocío Parra,Angela González,Sergio Molgó,Montserrat Droppelmann,Nicolás Acevedo,Francisco Peña,José Uribe,Pablo
author_facet	Rodríguez,Rocío Parra,Angela González,Sergio Molgó,Montserrat Droppelmann,Nicolás Acevedo,Francisco Peña,José Uribe,Pablo
author_sort	Rodríguez,Rocío
title	Entendiendo las terapias actuales en melanoma metastásico
title_short	Entendiendo las terapias actuales en melanoma metastásico
title_full	Entendiendo las terapias actuales en melanoma metastásico
title_fullStr	Entendiendo las terapias actuales en melanoma metastásico
title_full_unstemmed	Entendiendo las terapias actuales en melanoma metastásico
title_sort	entendiendo las terapias actuales en melanoma metastásico
publisher	Sociedad Médica de Santiago
publishDate	2016
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872016001100011
work_keys_str_mv	AT rodriguezrocio entendiendolasterapiasactualesenmelanomametastasico AT parraangela entendiendolasterapiasactualesenmelanomametastasico AT gonzalezsergio entendiendolasterapiasactualesenmelanomametastasico AT molgomontserrat entendiendolasterapiasactualesenmelanomametastasico AT droppelmannnicolas entendiendolasterapiasactualesenmelanomametastasico AT acevedofrancisco entendiendolasterapiasactualesenmelanomametastasico AT penajose entendiendolasterapiasactualesenmelanomametastasico AT uribepablo entendiendolasterapiasactualesenmelanomametastasico
_version_	1718436915016892416

Entendiendo las terapias actuales en melanoma metastásico

Ejemplares similares